Primary Cell Lines Derived from the Human Gall Bladder for the Purpose of Gene and Cell Therapy for Metabolic Liver Disorders

Overview

About this study

This research study will help us to improve our understanding of normal liver and gallbladder function. Additionally, this research study will be used to try to discover new therapies for treating liver disease using gallbladder cells.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18 to 75 (participants undergoing a liver transplant)

Exclusion Criteria: 

  • Those not undergoing a liver transplant and younger than 18 or older than 75.
  • No gallbladders will be collected from patients with known infection with either HIV or Hepatitis C.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Scott Nyberg, M.D., Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20315198

Mayo Clinic Footer